<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/organon-wins-us-approval-widen-use-arthritis-biosimilar-drug-2026-06-10/">Organon wins US approval to widen use of arthritis biosimilar drug</a>
    </div>

      <div class="me-0 me-md-5">
        Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, ​a biosimilar to Roche&#39;s Actemra, to treat ‌a life‑threatening immune reaction in some cancer patients and COVID-19 in patients needing breathing support.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/21/3299069/0/en/Hanmi-Pharmaceutical-Partners-with-Organon-to-Export-Combination-Therapies-to-Southeast-Asia.html">Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia</a>
    </div>

      <div class="me-0 me-md-5">
        Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon&#39;s Malaysia office to discuss the expansion of Hanmi&#39;s combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agr...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260515139840/en/Organon-to-Present-New-Research-on-Access-and-Value-at-ISPOR-2026/">Organon to Present New Research on Access and Value at ISPOR 2026</a>
    </div>

      <div class="me-0 me-md-5">
        JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women&#39;s health, biosimilar and general medicines portfolio at ISPOR 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260430180575/en/Organon-Reports-Results-for-the-First-Quarter-Ended-March-31-2026/">Organon Reports Results for the First Quarter Ended March 31, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions   Q1 2026   Q1 2025   VPY   VPY ex-FX Women&#39;s Health   $ 389   $ 463   (16)%   (19)% General Medicines                 Biosimilars     173     141   23%   21% Established Brands     880     887   (1)%   (7)% Other (1)     18    ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260429184636/en/Organon-Cancels-First-Quarter-Earnings-Call/">Organon Cancels First Quarter Earnings Call</a>
    </div>

      <div class="me-0 me-md-5">
        JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company&#39;s April 26, 2026 announcement that it has entered into a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260428591884/en/Organon-Co.-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Organon-Co.---OGN/">Organon &amp; Co. Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon &amp; Co. - OGN</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK CITY &amp; NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Organon &amp; Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that t...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/coverage/stock-market-today/2026/04/27/stock-market-today-april-27-organon-shares-surge-after-sun-pharma-agrees-to-acquire-company-in-all-cash-deal/">Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal</a>
    </div>

      <div class="me-0 me-md-5">
        Expand NYSE: OGN Organon &amp; Co. Today&#39;s Change (16.87%) $1.90 Current Price $13.16 Key Data Points Market Cap $2.9B Day&#39;s Range $13.15 - $13.24 52wk Range $5.69 - $13.24 Volume 134M Avg Vol 5.8M Gross Margin 53.59% Dividend Yield 0.71% Organon (OGN +16.87%), a women&#39;s health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutica...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Organon-Co-US68622V1061">Organon &amp; Co.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/27/3281835/0/en/Johnson-Fistel-Investigates-Potential-Breaches-of-Fiduciary-Duty-in-Connection-with-the-Proposed-Acquisition-of-Organon-by-Sun-Pharmaceutical.html">Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Organon &amp; Co. (NYSE: OGN) breached their fiduciary duties in connection with the proposed sale of the company to Sun Pharmaceutical.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Organon-Co-US68622V1061/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>